updat model follow result
issuanc report earn
issu report day shortli releas
result remind total revenu declin
rest world ex-curr
re-affirmed guidanc includ revenu guidanc
billion billion adjust ep
guidanc new revenu estim
billion vs previou estim billion new
adjust ep estim vs previou estim
current consensu
thought gener advair june pdufa
approv could potenti posit stock long-
delay program base experi discuss
investor think risk may price
expect also believ opportun may turn
modest believ first advair declin rapidli
yoy gsk transit patient new product
price categori fall second expect gsk launch
author gener gain approv assum
price drop approxim gener take share
take approxim share gener arriv
approxim sale opportun assum compani
averag gross margin current assum tax rate arriv
ep contribut approxim approxim
per quarter clearli approv would posit vs
altern may halo effect rest pipelin
opinion financi contribut would modest
addit advair gener outlin number
gener opportun ahead includ gener restasi
remain market perform share slightli revis
price target
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap ep exclud one-tim item includ restructur
compani prioriti stock list
compani data secur llc estim reuter
factset secur llc estim
million unless otherwis note
compani file factset secur llc estim
previou new incom segment revenu north rest chg segment revenu north rest profit expens expens interest incom incom incom per
price target
dcf-deriv price target base discount rate termin ev/ebitda multipl
risk includ gener drug market dynam like less favor prior
year gener compani may less polit cover go forward gener drug
penetr may alreadi peak epipen concentr sale profit govern risk
sec investig lawsuit integr risk tie meda deal
remain market perform believ face anoth potenti headwind gener a/b
rate epipen emerg believ like also believ gener sector
rapid margin-declin environ caution warrant
mylan inc base canonsburg pa domicil netherland among world
largest gener pharmaceut compani engag develop licens manufactur
market distribut gener proprietari pharmaceut product primari specialti
pharma product epipen treatment acut allerg reaction
